Selank vs KPV

At first glance, these two peptides look very different. One targets anxiety. The other targets the gut. They have no shared receptor or primary mechanism. They also have no shared clinical use.

Still, the comparison makes sense. Both are small synthetic peptides. Both come from molecules that act on the immune system. Both change inflammatory cytokines. A cytokine is a signaling protein used by immune cells. They do this in different tissues. They belong to a growing group of peptides that link immune function with specific organ tasks.

Selank is a 7-amino-acid peptide. It comes from tuftsin. Tuftsin is an immune-signaling molecule made of 4 amino acids. A nasal spray delivers Selank. It acts on cytokines in the brain. It lowers levels of the cytokines IL-6 and TNF-alpha. It also blocks an enzyme called enkephalinase. This enzyme breaks down natural opioids, so blocking it may raise opioid tone. It also acts on the GABA system. GABA is the brain's main calming signal [PMID: 21493795]. Its main task is to reduce anxiety.

KPV is a 3-amino-acid peptide. The sequence is Lys-Pro-Val. It comes from a hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH. KPV is the end piece of this hormone. This piece keeps its anti-inflammatory action. But it lacks the hormone's effect on skin pigment. KPV's main job is to lower the cytokines TNF-alpha and IL-6 in the gut. It also helps seal the gut wall [PMID: 18495773]. Its main task is to lower gut inflammation.

This comparison shows how immune signals can be used in different tissues. Selank acts on brain inflammation. KPV acts on gut inflammation. They are distant cousins in the immune-peptide family. They are not direct competitors.

Selank and KPV both lower the cytokines TNF-alpha and IL-6. But they act in different body areas. They use different receptors. They also have different results.

Selank acts in the brain. It is derived from tuftsin. Tuftsin is a molecule that wakes up immune cells. In preclinical tests, a nasal spray of Selank lowered IL-6 and TNF-alpha in the brain. It did this in the hippocampus and cortex. These areas link to stress and anxiety [PMID: 21493795]. This action layers on top of Selank's other jobs. It blocks enkephalinase to raise natural opioid levels. It also acts on the GABA system [PMID: 21833148]. The total effect is a multi-pathway treatment. It lowers nerve firing through two routes at once.

KPV acts in the gut. It is a piece of the hormone alpha-MSH. KPV blocks a protein called NF-kappaB. This protein acts as a master switch for inflammation genes. By blocking it, KPV lowers TNF-alpha, IL-6, and other inflammatory signals in the gut [PMID: 18495773]. This matters in gut diseases. In those cases, NF-kappaB is overactive and drives swelling.

KPV also helps seal the gut wall. This wall is one layer of cells joined by tight junctions. A tight junction is a protein seal between cells. In Crohn's disease and ulcerative colitis, this seal breaks down. KPV may raise the level of junction proteins. It may also help cells survive. This keeps the wall sealed under stress [PMID: 18495773].

The key difference is the body area. Selank's action matters in the brain. There, swelling links to anxiety and stress. KPV's action matters in the gut. There, swelling links to bowel disease. Both are anti-inflammatory peptides. But they work in separate body areas with little overlap.

Both Selank and KPV are small synthetic peptides. Both come from molecules that act on the immune system. Selank comes from tuftsin. Tuftsin helps wake up immune cells. KPV comes from alpha-MSH. That hormone fights inflammation. Both keep the parent molecule's immune action. Both also add drug-style traits. They resist breakdown and act in select spots.

Both lower the inflammatory cytokines TNF-alpha and IL-6. This shared action is the main reason to compare them. The body areas differ, but the target proteins match. TNF-alpha and IL-6 act in almost every inflammatory case. Both peptides lower their output by changing the signals that turn them on.

Both are at the research stage. Selank has more human test data. It is approved in Russia for generalized anxiety disorder. KPV's published data is mostly from animals. Tests used gut swelling and skin swelling in animals [PMID: 18495773]. Both are sold for research use only outside Russia.

Both show safe results in published data. No serious side effects or organ damage have appeared. No sign of dependence has appeared. Both fit a trend. The trend favors small peptides that hit one target. The goal is a focused effect rather than a full immune shutdown.

The main difference is the body area. Selank works in the brain. It changes brain swelling, opioid tone, and GABA signaling. KPV works in the gut. It blocks NF-kappaB and helps seal the gut wall. These are different organ systems. They have different cell types and different health impacts.

Size differs greatly. Selank has 7 amino acids. Its weight is 752 Da. KPV has 3 amino acids. Its weight is 357 Da. Three amino acids is near the smallest size for an active peptide. This tiny size helps KPV work when swallowed. That is rare for peptides.

The delivery method also differs. Selank uses a nasal spray. It reaches the brain through the smell nerve. KPV can use a skin shot, a swallow, or a cream. Its small size allows gut uptake. This suits its gut target. It is also easier for labs that lack shots or sprays.

The two peptides change cytokines in different ways. Selank works upstream. It acts on the tuftsin pathway, which then alters cytokines. KPV acts directly on NF-kappaB. It blocks this switch from turning on inflammation genes. Selank shifts the signal. KPV cuts the signal. This difference matters for mechanism tests.

Selank has extra jobs that KPV lacks. It blocks enkephalinase to raise opioid tone. It acts on GABA. It also reduces anxiety. KPV has extra jobs that Selank lacks. It supports tight junctions to seal the gut. It helps cells survive. It may also lower the pigment effect of alpha-MSH. KPV was built to cut that pigment effect.

The health use and test stage differ. Selank has passed human tests. It is approved in Russia. KPV's data is mostly from animal tests of gut and skin swelling. Human data is limited. Selank is further along in testing. Keep this gap in mind when weighing both sets of data.

Choose Selank if your work involves brain swelling, anxiety, or brain immune signaling. It lowers brain cytokines. It raises opioid tone. It acts on GABA. This mix makes it a multi-pathway tool for anxiety. It suits tests on generalized anxiety, stress-related brain swelling, and immune-brain links.

It is also useful for one question. Can immune activation from infection drive brain anxiety? Selank helps test the cytokine link in that path.

Choose KPV if your work involves gut swelling, a weak gut wall, or gut immune control. It blocks NF-kappaB. It helps seal the gut wall. This suits tests on bowel disease, weak gut walls, and gut inflammation. Swallowing KPV is a plus for gut tests. The peptide reaches the gut by mouth.

There is no clinical case where you must pick one over the other. They serve different organs. A researcher testing the gut-brain link may use both. But each tool serves one end of that link. They are not interchangeable.

KPV by mouth is simpler for labs without shot gear. Selank by nose is also non-invasive. But it needs a spray and a set method.